Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Dr Merryman on the Evolution of MRD Assays in Lymphoma

September 05, 2024

Video

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

September 05, 2024

Podcast

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Clinical Pearls and Impacts to Practice from EHA 2024

September 05, 2024

Video

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Dr Yekedüz on a Case Study of Adjuvant Treatment Options in ccRCC

September 04, 2024

Video

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

Baseline Radiologic Tumor Burden Is Prognostic for OS in Metastatic ccRCC

September 04, 2024

Article

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.

Dr Tolaney on the Development of TROP2-Directed ADCs in Breast Cancer

September 03, 2024

Video

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Abemaciclib Monotherapy Elicits No Response in Advanced RCC: Where the Field is Headed From Here

August 30, 2024

Article

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Dr Tolaney on the Sequential Use of ADCs in Breast Cancer

August 30, 2024

Video

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

August 29, 2024

Video

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

August 29, 2024

Video

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29, 2024

Video

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Key Takeaways and Closing Thoughts on ADCs

August 29, 2024

Video

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

The Future for HER2-Directed ADCs

August 29, 2024

Video

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

August 29, 2024

Video

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29, 2024

Article

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Dr McGregor on the Investigation of Abemaciclib Monotherapy in ccRCC

August 28, 2024

Video

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Dr Yekedüz on the Importance of the KEYNOTE-564 Trial in Adjuvant ccRCC

August 27, 2024

Video

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Biomarker-Driven Approaches Could Refine Treatment Selection in RCC

August 26, 2024

Article

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26, 2024

Video

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Dr Yekedüz on the Benefits of Biomarker-Driven Treatment in Kidney Cancer

August 26, 2024

Video

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.